This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190306005182/en/

Urovant Sciences Appoints James Robinson to its Board of Directors (Photo: Business Wire)
“Jim’s extensive leadership, knowledge and experience in thebiopharmaceutical space combined with his unique understanding of theurology market will help inform Urovant’s strategies and growthopportunities,” said
“Jim has demonstrated unwavering leadership in the competitive and
complex biopharmaceutical market,” said
Mr. Robinson has more than 27 years of commercial and operations experience in the biopharmaceutical industry, specifically in the urology, oncology, cardiovascular, infectious disease, hepatitis and CNS markets. Since
Prior to
“I am pleased to join Urovant’s board and work with a company that is passionate about developing and commercializing innovative products to address the needs of urology patients who oftentimes suffer in silence,” said Mr. Robinson. “I look forward to working with Keith and his leadership team.”
Mr. Robinson serves on the Board of Directors for
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005182/en/
Source:
Investor inquiries: Investors@Urovant.com
Media inquiries: Media@Urovant.com